Is PYXS or MREO more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Mereo BioPharma Group N/A -74.82% -64.28%

Mereo BioPharma Group (MREO) Competitors

$0.38 +0.01 (+3.52%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.38 0.00 (-0.21%)

As of 10/2/2026 07:56 PM Eastern

Compare

MREO vs. MGNX, CAMP, IVVD, PYXS, and AKBA

Should you buy Mereo BioPharma Group stock or one of its competitors? Mereo BioPharma Group's main competitors and comparable companies include MacroGenics (MGNX), CAMP4 Therapeutics (CAMP), Invivyd (IVVD), Pyxis Oncology (PYXS), and Akebia Therapeutics (AKBA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mereo BioPharma Group compare to MacroGenics?

Mereo BioPharma Group (NASDAQ:MREO) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Mereo BioPharma Group has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	121.30	-$41.88M	-$0.04	N/A
MacroGenics	$149.50M	1.53	-$74.62M	-$0.22	N/A

In the previous week, MacroGenics' average media sentiment score of 1.76 beat Mereo BioPharma Group's score of 0.00 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
MacroGenics	Very Positive

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mereo BioPharma Group has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Mereo BioPharma Group's return on equity of -74.82% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
MacroGenics	-8.70%	-109.26%	-18.70%

Mereo BioPharma Group presently has a consensus target price of $1.67, suggesting a potential upside of 338.83%. MacroGenics has a consensus target price of $6.33, suggesting a potential upside of 76.91%. Given Mereo BioPharma Group's higher probable upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Mereo BioPharma Group has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Mereo BioPharma Group beats MacroGenics on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to CAMP4 Therapeutics?

Mereo BioPharma Group (NASDAQ:MREO) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Mereo BioPharma Group has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Mereo BioPharma Group's return on equity of -74.82% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

In the previous week, CAMP4 Therapeutics had 9 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 beat CAMP4 Therapeutics' score of -0.12 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
CAMP4 Therapeutics	Neutral

62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Mereo BioPharma Group has higher earnings, but lower revenue than CAMP4 Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	121.30	-$41.88M	-$0.04	N/A
CAMP4 Therapeutics	$3.50M	71.71	-$80.40M	-$2.32	N/A

Mereo BioPharma Group has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Mereo BioPharma Group presently has a consensus price target of $1.67, indicating a potential upside of 338.83%. CAMP4 Therapeutics has a consensus price target of $10.17, indicating a potential upside of 154.17%. Given Mereo BioPharma Group's higher possible upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Mereo BioPharma Group beats CAMP4 Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Invivyd?

Invivyd (NASDAQ:IVVD) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Invivyd has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Mereo BioPharma Group has lower revenue, but higher earnings than Invivyd. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.54	-$52.49M	-$0.33	N/A
Mereo BioPharma Group	$500K	121.30	-$41.88M	-$0.04	N/A

Mereo BioPharma Group has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

In the previous week, Invivyd had 11 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 11 mentions for Invivyd and 0 mentions for Mereo BioPharma Group. Invivyd's average media sentiment score of 1.10 beat Mereo BioPharma Group's score of 0.00 indicating that Invivyd is being referred to more favorably in the media.

Company	Overall Sentiment
Invivyd	Positive
Mereo BioPharma Group	Neutral

70.4% of Invivyd shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 873.12%. Mereo BioPharma Group has a consensus price target of $1.67, suggesting a potential upside of 338.83%. Given Invivyd's stronger consensus rating and higher probable upside, equities analysts plainly believe Invivyd is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Invivyd beats Mereo BioPharma Group on 11 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Mereo BioPharma Group has lower revenue, but higher earnings than Pyxis Oncology. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	12.88	-$79.62M	-$1.41	N/A
Mereo BioPharma Group	$500K	121.30	-$41.88M	-$0.04	N/A

Pyxis Oncology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Pyxis Oncology presently has a consensus target price of $8.75, indicating a potential upside of 308.88%. Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 338.83%. Given Mereo BioPharma Group's higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mereo BioPharma Group's return on equity of -74.82% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

In the previous week, Pyxis Oncology had 12 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 12 mentions for Pyxis Oncology and 0 mentions for Mereo BioPharma Group. Pyxis Oncology's average media sentiment score of 0.22 beat Mereo BioPharma Group's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Neutral
Mereo BioPharma Group	Neutral

Summary

Mereo BioPharma Group beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Akebia Therapeutics?

Mereo BioPharma Group (NASDAQ:MREO) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Mereo BioPharma Group has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Mereo BioPharma Group's return on equity of -74.82% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

In the previous week, Akebia Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Akebia Therapeutics and 0 mentions for Mereo BioPharma Group. Akebia Therapeutics' average media sentiment score of 0.45 beat Mereo BioPharma Group's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
Akebia Therapeutics	Neutral

Akebia Therapeutics has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	121.30	-$41.88M	-$0.04	N/A
Akebia Therapeutics	$236.20M	1.01	-$5.34M	-$0.11	N/A

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mereo BioPharma Group has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Mereo BioPharma Group presently has a consensus price target of $1.67, suggesting a potential upside of 338.83%. Akebia Therapeutics has a consensus price target of $3.90, suggesting a potential upside of 350.87%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Akebia Therapeutics beats Mereo BioPharma Group on 9 of the 16 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.65M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-9.50	13.06	275.66	26.04
Price / Sales	121.30	1,295.73	609.44	91.76
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.46	16.63	10.93	6.31
Net Income	-$41.88M	-$22.71M	$3.51B	$362.16M
7 Day Performance	2.65%	-2.99%	-2.00%	-1.66%
1 Month Performance	39.53%	-10.60%	-6.15%	-4.50%
1 Year Performance	-81.38%	19.44%	7.44%	2.06%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.0413 of 5 stars	$0.38 +3.5%	$1.67 +338.8%	-81.4%	$60.65M	$500K	N/A	39	Analyst Forecast Gap Up
MGNX MacroGenics	2.2475 of 5 stars	$3.86 -5.0%	$6.33 +64.3%	+101.1%	$244.29M	$149.50M	N/A	293	Positive News
CAMP CAMP4 Therapeutics	3.7493 of 5 stars	$3.87 +0.5%	$9.71 +151.0%	+33.3%	$243.85M	$3.50M	N/A	644	Analyst Forecast
IVVD Invivyd	3.6763 of 5 stars	$0.83 -13.2%	$8.00 +869.7%	-29.1%	$242.88M	$53.43M	N/A	122	Positive News Analyst Forecast Gap Up High Trading Volume
PYXS Pyxis Oncology	2.6822 of 5 stars	$2.91 +0.2%	$8.75 +201.2%	-16.7%	$242.31M	$13.86M	N/A	56

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. MGNX, CAMP, IVVD, PYXS, and AKBA

How does Mereo BioPharma Group compare to MacroGenics?

Summary

How does Mereo BioPharma Group compare to CAMP4 Therapeutics?

Summary

How does Mereo BioPharma Group compare to Invivyd?

Summary

How does Mereo BioPharma Group compare to Pyxis Oncology?

Summary

How does Mereo BioPharma Group compare to Akebia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. MGNX, CAMP, IVVD, PYXS, and AKBA

How does Mereo BioPharma Group compare to MacroGenics?

Which has stronger valuation and earnings, MREO or MGNX?

Does the media refer more to MREO or MGNX?

Do institutionals & insiders believe in MREO or MGNX?

Is MREO or MGNX more profitable?

Do analysts recommend MREO or MGNX?

Which has more risk & volatility, MREO or MGNX?

Summary

How does Mereo BioPharma Group compare to CAMP4 Therapeutics?

Is MREO or CAMP more profitable?

Does the media prefer MREO or CAMP?

Do institutionals and insiders have more ownership in MREO or CAMP?

Which has higher earnings and valuation, MREO or CAMP?

Which has more volatility and risk, MREO or CAMP?

Do analysts recommend MREO or CAMP?

Summary

How does Mereo BioPharma Group compare to Invivyd?

Which has more risk and volatility, IVVD or MREO?

Which has preferable valuation & earnings, IVVD or MREO?

Is IVVD or MREO more profitable?

Does the media refer more to IVVD or MREO?

Do institutionals & insiders hold more shares of IVVD or MREO?

Do analysts rate IVVD or MREO?

Summary

How does Mereo BioPharma Group compare to Pyxis Oncology?

Which has stronger valuation and earnings, PYXS or MREO?

Which has more volatility & risk, PYXS or MREO?

Do analysts rate PYXS or MREO?

Do institutionals & insiders have more ownership in PYXS or MREO?

Is PYXS or MREO more profitable?

Does the media favor PYXS or MREO?

Summary

How does Mereo BioPharma Group compare to Akebia Therapeutics?

Is MREO or AKBA more profitable?

Does the media refer more to MREO or AKBA?

Which has stronger valuation & earnings, MREO or AKBA?

Do institutionals & insiders hold more shares of MREO or AKBA?

Which has more volatility and risk, MREO or AKBA?

Do analysts prefer MREO or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools